In this engaging presentation, Noelle Frey, MD, offers a case report to illustrate recent advances in the field of allogeneic SCT. Among the findings noted by Dr. Frey: ASCT is both feasible and promising in patients 65 - 75 years of age; molecular predictors of poor outcome can be prognostic for relapse and survival; new therapies are available for steroid-refractory GVHD, including ibrutinib, ruxolitinib and Maraviroc; and studies in maintenance therapy with TKIs, FLT3 inhibitors and hypomethylating agents hold the promise of relapse prevention in the post-ASCT environment.
Related Links:
Enrolling Clinical Trials: Umbilical Cord Blood Transplantation vs Haploidentical Transplantation for Patients with Hematological Malignancies
Dr Frey’s Doximity Profile
Dr. Frey’s Penn Profile
Published
March 8, 2018
Created by
BROADCASTMED